Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPEPPS | P55786 | 12/20 | 0.87 |
| ▸ | ANPEP | P15144 | 10/20 | 0.85 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.85 |
| ▸ | TP53 | P04637 | 2/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.85 |
| ▸ | LMNA | P02545 | 1/20 | 0.85 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.85 |
| ▸ | HTT | P42858 | 1/20 | 0.84 |
| ▸ | NPC1 | O15118 | 1/20 | 0.84 |
| ▸ | RAB9A | P51151 | 1/20 | 0.84 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25224697 | 0.94 | NPEPPS (0.87) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| SCHEMBL20257206 | 0.92 | NPEPPS (0.84) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL14583945 | 0.92 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL21306559 | 0.92 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL3042415 | 0.92 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL24206459 | 0.92 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL22409382 | 0.92 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL22348910 | 0.92 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL21481061 | 0.92 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL20815730 | 0.92 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1998026042-A1 | INDUCED CHROMOSOMAL DELETION | THE JACKSON LABORATORY (US) | 1998-06-18 | — | — | WO | claimed |
| EP-3775261-B1 | TARGET BINDING MOIETY COMPOSITIONS AND METHODS OF USE | GUANGZHOU CHENGYUAN BIOIMMUNOLOGY TECH CO LTD (CN) | 2025-09-17 | — | — | EP | disclosed |
| EP-2989239-B2 | SELECTION OF FAB FRAGMENTS USING RIBOSOMAL DISPLAY TECHNOLOGY | SUTRO BIOPHARMA INC (US) | 2025-01-15 | — | — | EP | disclosed |
| US-12116572-B2 | Target binding moiety compositions and methods of use | Guangzhou Chengyuan Bioimmunology Technology Co., Ltd. (CN) | 2024-10-15 | — | — | US | disclosed |
| US-12077557-B2 | Puromycin-based probes and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-09-03 | — | — | US | disclosed |
| US-20240240259-A1 | METHODS AND COMPOUNDS FOR NEOANTIGEN VACCINES | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE | 2024-07-18 | — | — | US | disclosed |
| EP-4313129-A1 | METHODS AND COMPOUNDS FOR NEOANTIGEN VACCINES | The Translational Genomics Research Institute (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20230279384-A1 | TARGET BINDING MOIETY COMPOSITIONS AND METHODS OF USE | Guangzhou Chengyuan Bioimmunology Technology Co., Ltd. (CN) | 2023-09-07 | — | — | US | disclosed |
| US-20230193203-A1 | NEOANTIGEN-INFORMED TUMOR-INFILTRATING LYMPHOCYTE CANCER IMMUNOTHERAPY | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE | 2023-06-22 | — | — | US | disclosed |
| EP-4142779-A1 | NEOANTIGEN-INFORMED TUMOR-INFILTRATING LYMPHOCYTE CANCER IMMUNOTHERAPY | The Translational Genomics Research Institute (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20120266329-A1 | Nucleic Acids and Proteins and Methods for Making and Using Them | BP CORPORATION NORTH AMERICA INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-8119385-B2 | Nucleic acids and proteins and methods for making and using them | BP CORPORATION NORTH AMERICA INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110296543-A1 | NUCLEIC ACIDS AND PROTEINS AND METHODS FOR MAKING AND USING THEM | THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-01 | — | — | US | disclosed |
| EP-2230312-A1 | Probe compound for detecting and isolating enzymes and means and methods using the same | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2010-09-22 | — | — | EP | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20100011456-A1 | Nucleic Acids and Proteins and Methods for Making and Using Them | VERENIUM CORPORATION (US) | 2010-01-14 | — | — | US | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
| EP-1165800-A2 | MITOMYCIN BIOSYNTHETIC GENE CLUSTER | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000053737-A2 | MITOMYCIN BIOSYNTHETIC GENE CLUSTER | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2000-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | NPEPPS 2401/4885ANPEP 695/4885SMN1; SMN2 862/4885 |
| US-12077557-B2 | Puromycin-based probes and methods of use thereof | NPEPPS, PABPC4, PABPC1 | NPEPPS 1/4885ANPEP 72/4885SMN1; SMN2 386/4885 |
| US-20120266329-A1 | Nucleic Acids and Proteins and Methods for Making and Using Them | POLN, POLM, POLI | NPEPPS 186/4885ANPEP 111/4885SMN1; SMN2 1508/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | NPEPPS 1666/4885ANPEP 766/4885SMN1; SMN2 1238/4885 |
| US-20100011456-A1 | Nucleic Acids and Proteins and Methods for Making and Using Them | POLN, POLM, POLI | NPEPPS 186/4885ANPEP 111/4885SMN1; SMN2 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.